2-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)-N-methylacetamide | 1417653-47-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)-N-methylacetamide
• 英文别名: 2-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]-N-methylacetamide
• CAS: 1417653-47-4
• 化学式: C₁₅H₁₂I₃NO₃
• 分子量: 634.979
• InChiKey: JPXYHNATOUPESC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  替拉曲考 、 甲胺 在 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以87%的产率得到2-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)-N-methylacetamide
  参考文献：
  名称：

  [EN] AMIDE PRODRUGS OF SMALL MOLECULE NUCLEAR RECEPTOR MODULATORS
  [FR] PROMÉDICAMENTS À BASE D'AMIDE DE MODULATEURS DE RÉCEPTEUR NUCLÉAIRE DE PETITES MOLÉCULES

  摘要：

  本文提供了用于中枢神经系统疾病的药用活性剂的新型酰胺前药形式。

  公开号：

  WO2019168842A1

文献信息

• SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY
  申请人：Fujii Naoaki

  公开号：US20140288077A1

  公开（公告）日：2014-09-25

  In one aspect, the invention relates to substituted 4-phenoxyphenol analogs, derivatives thereof, and related compounds, which are useful as inhibitors of proliferating cell nuclear antigen (PCNA); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating hyperproliferative disorders associated with PCNA using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明涉及替代的4-苯氧基苯酚类似物、其衍生物和相关化合物，它们可用作增殖细胞核抗原（PCNA）的抑制剂；制备这些化合物的合成方法；包含这些化合物的制药组合物；以及使用这些化合物和组合物治疗与PCNA相关的高增殖性疾病的方法。本摘要旨在作为搜索特定领域的扫描工具，不限制本发明。
• Small molecule inhibitors of PCNA/PIP-box interaction suppress translesion DNA synthesis
  作者：Marcelo Actis、Akira Inoue、Benjamin Evison、Scott Perry、Chandanamali Punchihewa、Naoaki Fujii

  DOI：10.1016/j.bmc.2013.01.022

  日期：2013.4

  Proliferating cell nuclear antigen (PCNA) is an essential component for DNA replication and DNA damage response. Numerous proteins interact with PCNA through their short sequence called the PIP-box to be promoted to their respective functions. PCNA supports translesion DNA synthesis (TLS) by interacting with TLS polymerases through PIP-box interaction. Previously, we found a novel small molecule inhibitor of the PCNA/PIP-box interaction, T2AA, which inhibits DNA replication in cells. In this study, we created T2AA analogues and characterized them extensively for TLS inhibition. Compounds that inhibited biochemical PCNA/PIP-box interaction at an IC50 <5 mu M inhibited cellular DNA replication at 10 mu M as measured by BrdU incorporation. In cells lacking nucleotide-excision repair activity, PCNA inhibitors inhibited reactivation of a reporter plasmid that was globally damaged by cisplatin, suggesting that the inhibitors blocked the TLS that allows replication of the plasmid. PCNA inhibitors increased gamma H2AX induction and cell viability reduction mediated by cisplatin. Taken together, these findings suggest that inhibitors of PCNA/PIP-box interaction could chemosensitize cells to cisplatin by inhibiting TLS. (C) 2013 Elsevier Ltd. All rights reserved.
• A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators
  作者：Skylar J. Ferrara、Thomas S. Scanlan

  DOI：10.1021/acs.jmedchem.0c00868

  日期：2020.9.10

  The blood-brain barrier is a major impediment for targeted central nervous system (CNS) therapeutics, especially with carboxylic acid-containing drugs. Nuclear receptor modulators, which often feature carboxylic acid motifs for target engagement, have emerged as a class of potentially powerful therapeutics for neurodegenerative CNS diseases. Herein is described a prodrug strategy that directs the biodistribution of parent drug nuclear receptor modulators into the CNS while masking them as functional receptor ligands in the periphery. This prodrug strategy targets a specific amidase, fatty acid amide hydrolase (FAAH), an enzyme with enriched expression in the CNS. Our results demonstrate that this prodrug strategy can be generalized to a variety of carboxylic acid-containing drug structures that satisfy the structural requirements of blood-brain barrier diffusion and FAAH substrate recognition.
• AMIDE PRODRUGS OF SMALL MOLECULE NUCLEAR RECEPTOR MODULATORS
  申请人：OREGON HEALTH & SCIENCE UNIVERSITY

  公开号：US20210087137A1

  公开（公告）日：2021-03-25

  Provided herein are novel amide prodrug forms of pharmaceutically active agents useful for central nervous system disorders.
• [EN] AMIDE PRODRUGS OF SMALL MOLECULE NUCLEAR RECEPTOR MODULATORS<br/>[FR] PROMÉDICAMENTS À BASE D'AMIDE DE MODULATEURS DE RÉCEPTEUR NUCLÉAIRE DE PETITES MOLÉCULES
  申请人：UNIV OREGON HEALTH & SCIENCE

  公开号：WO2019168842A1

  公开（公告）日：2019-09-06

  Provided herein are novel amide prodrug forms of pharmaceutically active agents useful for central nervous system disorders.

  本文提供了用于中枢神经系统疾病的药用活性剂的新型酰胺前药形式。